/HIMS
HIMS Stock - Hims & Hers Health, Inc.
Healthcare|Medical - Equipment & ServicesNYSE
$35.56+2.27%
+$0.79 (+2.27%) • Dec 19
49
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.7
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).93
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.24
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+21.7%upside
Target: $43.28
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HIMS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$35.20 – $35.92
TARGET (TP)$43.29
STOP LOSS$32.72
RISK/REWARD1:2.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.41
52W High$72.98
52W Low$23.97
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.48B | $872.00M | $526.92M | $271.88M | $148.76M |
| Gross Profit | $1.17B | $714.95M | $408.72M | $204.49M | $109.45M |
| Gross Margin | 79.5% | 82.0% | 77.6% | 75.2% | 73.6% |
| Operating Income | $61.90M | $-29,453,000 | $-68,697,000 | $-115,042,000 | $-15,144,000 |
| Net Income | $126.04M | $-23,546,000 | $-65,678,000 | $-107,659,000 | $-18,114,000 |
| Net Margin | 8.5% | -2.7% | -12.5% | -39.6% | -12.2% |
| EPS | $0.58 | $-0.11 | $-0.32 | $-0.58 | $-0.51 |
Company Overview
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
48%
Hold / Neutral
8
38%
Sell / Underperform
3
14%
Analyst Consensus🔴 Bearish
10 Bullish11 Neutral/Bearish
Price Targets
$21
Average Target
↓ 39.9% Downside
Now
$4
Low
$21
Average
$65
High
Based on 23 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Overweight | $48 |
| October 21st 2025 | KeyBanc Capital Markets | Initiation | Sector Weight | - |
| June 23rd 2025 | Needham | Downgrade | Hold | - |
| June 4th 2025 | Needham | Reiterated | Buy | $65← $61 |
| April 29th 2025 | TD Cowen | Downgrade | Hold | $30 |
| February 18th 2025 | Morgan Stanley | Downgrade | Equal Weight | $60← $42 |
| January 10th 2025 | Citigroup | Downgrade | Sell | $25← $24 |
| January 7th 2025 | BTIG Research | Initiation | Buy | $35 |
| December 17th 2024 | Morgan Stanley | Initiation | Overweight | $42 |
| November 14th 2024 | BofA Securities | Downgrade | Underperform | - |
| August 22nd 2024 | Needham | Initiation | Buy | $24 |
| August 9th 2024 | Imperial Capital | Downgrade | In-line | - |
| May 22nd 2024 | Citigroup | Downgrade | Neutral | $20← $16 |
| April 16th 2024 | Jefferies | Downgrade | Hold | $15← $17 |
| April 10th 2024 | Canaccord Genuity | Initiation | Buy | $20 |
Earnings History & Surprises
HIMSBeat Rate
67%
Last 18 quarters
Avg Surprise
+40.7%
EPS vs Estimate
Beats / Misses
12/4
2 met exactly
Latest EPS
$0.06
Q4 2025
EPS Surprise History
Q1 24
+153.2%
$0.01vs$0.00
Q2 24
+316.7%
$0.05vs$0.01
Q3 24
+40.4%
$0.06vs$0.04
Q4 24
0.0%
$0.06vs$0.06
Q1 25
+22.2%
$0.11vs$0.09
Q2 25
+65.4%
$0.20vs$0.12
Q3 25
-5.6%
$0.17vs$0.18
Q4 25
-33.3%
$0.06vs$0.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 23, 2026 | $0.04 | — | — | — |
Q4 2025 | Nov 3, 2025 | $0.09 | $0.06 | -33.3% | ✗ MISS |
Q3 2025 | Aug 4, 2025 | $0.18 | $0.17 | -5.6% | ✗ MISS |
Q2 2025 | May 5, 2025 | $0.12 | $0.20 | +65.4% | ✓ BEAT |
Q1 2025 | Feb 24, 2025 | $0.09 | $0.11 | +22.2% | ✓ BEAT |
Q4 2024 | Nov 4, 2024 | $0.06 | $0.06 | 0.0% | = MET |
Q3 2024 | Aug 5, 2024 | $0.04 | $0.06 | +40.4% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $0.01 | $0.05 | +316.7% | ✓ BEAT |
Q1 2024 | Feb 26, 2024 | $0.00 | $0.01 | +153.2% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-0.03 | $-0.04 | -27.3% | ✗ MISS |
Q3 2023 | Aug 7, 2023 | $-0.06 | $-0.03 | +50.0% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $-0.07 | $-0.05 | +28.6% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.11 | $-0.09 | +18.2% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.10 | $-0.10 | 0.0% | = MET |
Q2 2022 | May 9, 2022 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q1 2022 | Feb 22, 2022 | $-0.10 | $-0.11 | -10.0% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.14 | $-0.09 | +35.7% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.16 | $-0.08 | +50.0% | ✓ BEAT |
Latest News
Hims & Hers has officially introduced the Hers platform, helping eligible women across the UK receive access to weight management care
📈 PositiveBenzinga•Dec 10, 2025, 10:45 AM
Barclays Initiates Coverage On Hims & Hers Health with Overweight Rating, Announces Price Target of $48
📈 PositiveBenzinga•Dec 9, 2025, 02:49 PM•Also:
Hims & Hers Health shares are trading higher after the company announced its international expansion into Canada, following the recent completion of its Livewell acquisition.
📈 PositiveBenzinga•Dec 4, 2025, 06:15 PM
Hims & Hers Expands Into Canada After Buying Local Health Platform Livewell
📈 PositiveBenzinga•Dec 4, 2025, 12:02 PM
Hims & Hers to Acquire YourBio; No Financial Terms Disclosed
➖ NeutralBenzinga•Dec 3, 2025, 02:04 PM
Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2%
📈 PositiveSeeking Alpha•Nov 17, 2025, 01:20 PM
Hims & Hers Health, Inc. Announces $250M Share Repurchase Program Authorization
📈 PositiveBenzinga•Nov 17, 2025, 01:04 PM
HIMS stock has given up its prior gain. Hims & Hers Health shares were trading higher after the company reported better-than-expected Q3 sales results.
➖ NeutralBenzinga•Nov 4, 2025, 06:24 PM
B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $32
➖ NeutralBenzinga•Nov 4, 2025, 11:45 AM
Hims & Hers Health shares are trading higher after the company reported better-than-expected Q3 sales results. Also, the company announced it is in active discussions to make Wegovy injections and Novo Nordisk's Oral Wegovy available on its platform.
📈 PositiveBenzinga•Nov 4, 2025, 11:09 AM•Also:
BTIG Reiterates Buy on Hims & Hers Health, Maintains $85 Price Target
📈 PositiveBenzinga•Nov 4, 2025, 09:14 AM
UPDATE: Hims & Hers Health Q3 Adj. EPS $0.09 Misses $0.10 Estimate, Sales $598.976M Beat $580.241M Estimate
➖ NeutralBenzinga•Nov 3, 2025, 10:53 PM
Hims & Hers Health in discussions with Novo Nordisk to sell Wegovy
📈 PositiveSeeking Alpha•Nov 3, 2025, 10:40 PM•Also:
Hims & Hers Health rises after narrowing 2025 EBITDA guidance, Q3 EPS miss
➖ NeutralSeeking Alpha•Nov 3, 2025, 10:16 PM
Hims & Hers Health shares are trading higher after the company reported better-than-expected Q3 sales results. Also, the company announced it is in active discussions to make Wegovy injections and Novo Nordisk's Oral Wegovy available on its platform.
📈 PositiveBenzinga•Nov 3, 2025, 09:29 PM•Also:
Hims & Hers Health Says Are In Active Discussions To Make Wegovy Injections And Novo Nordisk's Oral Wegovy Available Through Hims & Hers Platform
📈 PositiveBenzinga•Nov 3, 2025, 09:11 PM•Also:
Hims & Hers Health Narrows FY2025 Sales Guidance from $2.300B-$2.400B to $2.335B-$2.355B vs $2.341B Est
➖ NeutralBenzinga•Nov 3, 2025, 09:09 PM
Hims & Hers Health Sees Q4 Sales $605.000M-$625.000M vs $631.685M Est
📉 NegativeBenzinga•Nov 3, 2025, 09:09 PM
Hims & Hers Health Q3 EPS $0.06 Misses $0.09 Estimate, Sales $598.976M Beat $580.241M Estimate
➖ NeutralBenzinga•Nov 3, 2025, 09:08 PM
Keybanc Initiates Coverage On Hims & Hers Health with Sector Weight Rating
➖ NeutralBenzinga•Oct 21, 2025, 10:09 AM
Frequently Asked Questions about HIMS
What is HIMS's current stock price?
Hims & Hers Health, Inc. (HIMS) is currently trading at $35.56 per share. The stock has moved +2.27% today.
What is the analyst price target for HIMS?
The average analyst price target for HIMS is $43.29, based on 1 analyst.
What sector is Hims & Hers Health, Inc. in?
Hims & Hers Health, Inc. operates in the Healthcare sector, specifically within the Medical - Equipment & Services industry. The company is traded on the NYSE exchange.
What is HIMS's market cap?
Hims & Hers Health, Inc. has a market capitalization of $7.80 billion, making it a mid-cap company.
Does HIMS pay dividends?
No, Hims & Hers Health, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGN
Align Technology, Inc.
$157.69
Mkt Cap: $11.3B
BAX
Baxter International Inc.
$18.96
Mkt Cap: $9.7B
BMRN
BioMarin Pharmaceutical Inc.
$61.15
Mkt Cap: $11.7B
ENSG
The Ensign Group, Inc.
$181.39
Mkt Cap: $10.4B
HQY
HealthEquity, Inc.
$95.50
Mkt Cap: $8.3B
MRNA
Moderna, Inc.
$33.80
Mkt Cap: $13.2B
PEN
Penumbra, Inc.
$315.90
Mkt Cap: $12.4B
QGEN
Qiagen N.V.
$45.58
Mkt Cap: $9.9B
RVTY
Revvity, Inc.
$96.24
Mkt Cap: $11.4B
TECH
Bio-Techne Corporation
$58.27
Mkt Cap: $9.1B
Explore stocks similar to HIMS for comparison